The transcription factor PAX5 plays a key role in the commitment of hematopoietic precursors to the B-cell lineage, but its expression in acute leukemias has not been thoroughly investigated. Hereby, we analyzed routine biopsies from 360 acute leukemias of lymphoid (ALLs) and myeloid ( 
INTRODUCTION
PAX5, also named B-cell specific activator protein (BSAP), is a member of the highly conserved paired box (PAX)-domain family of transcription factors (1) . Targeted disruption of the PAX5 gene in mice blocks B-cell development at the earliest B-lineage committed precursor in the fetal liver and at the early pro-B-cell stage in the adult bone marrow (2) , thus providing evidence for the key role of PAX5 in the control of early B-lymphopoiesis. In particular, PAX5 fulfills a dual role in the commitment of the bone marrow multipotent progenitor to the B-lymphoid lineage (3), because it favors V H to D H J H gene rearrangement (2) and activates the expression of B-cell-specific genes [e.g. CD19 (4), Blk (5, 6) , mb-1/CD79a (7, 8) , and RAG2 (9)], while simultaneously repressing the lineage-promiscuous transcription of genes involved in other hematopoietic differentiation programs [such as Notch1 (10) , GATA-1, perforin, and M-CSF-R (3)]. Moreover, PAX5 maintains the identity and function of B cells during late B-lymphopoiesis (11, 12) . Accordingly, the expression of PAX5 is restricted to the B-lineage (13) (14) (15) , initiating in pro-B cells (2) and reaching the maximum level at the pre-B and mature B-cell differentiation stages (13) . Conversely, the PAX5 protein is not detectable in terminally differentiated plasma cells (13, 16) . PAX5 expression also occurs in the adult testis and in the mesencephalon and spinal cord during embryogenesis (17) , suggesting an important role in the development of these tissues.
Rearrangement of the PAX5 gene through reciprocal chromosomal translocations has been described in different types of B-cell malignancies (18 -23) , and, more recently, PAX5 has also been shown to be targeted by aberrant hypermutation in Ͼ50% of diffuse large B-cell lymphomas (24) . Immunohistochemical studies with specific polyclonal (14) and monoclonal antibodies (25) have clearly shown that PAX5 expression is restricted to lymphomas of B-cell lineage, including classical Hodgkin's lymphoma (15) . The latter finding has been taken as additional evidence for the B-cell origin of Hodgkin's and Reed-Sternberg cells (15) , and it has been proposed that immunostaining for PAX5 may be of value in the differential diagnosis between tumor cell-rich Hodgkin's lymphoma (PAX5 ϩ ) and ALKnegative T/null anaplastic large cell lymphoma (PAX5 Ϫ ; ref. 15) . Despite the extensive studies on lymphomas, only a few data are available on PAX5 expression in acute leukemias that are either based on the detection of PAX5 at the mRNA level [ (26) and not at the protein level] or limited to the description of PAX5 protein expression only in B-cell ALL (but not in T-cell ALL nor in AML) and only in comparison to that of CD20 (25) (but not to that of CD79a, which is a far more reliable marker of precursor B-cell neoplasms).
In this article, we used a specific monoclonal antibody (mAb) to investigate the expression of PAX5 in routine biopsies from a large number of acute leukemias of different lineages. The following evidence is provided: (a) PAX5 is a more specific marker than CD79a for the diagnosis of B-cell ALL; (b) among AMLs, PAX5 expression is specifically associated with the presence of the t(8;21) translocation; and (c) PAX5 expression in t(8;21)-AML correlates with that of CD19 and CD79a, which in B-cells are both known to be under the transcriptional control of PAX5 (4, 7, 8) .
MATERIALS AND METHODS
Samples. Paraffin blocks from a total of 35 normal and reactive bone marrow samples and 360 leukemia samples were retrieved from the files of the Hematopathology Sections of Perugia and Bologna Universities. The leukemia samples included bone marrow trephine biopsies from 150 B-cell ALLs, 47 T-cell ALLs, and 160 AMLs. Lymph node and skin biopsies from 3 T-cell ALL/lymphoblastic lymphomas, that we previously reported to bear the nondysulphide linked form of the TCR␥␦ (27) and to coexpress T-cell antigens and the CD79a molecule (28, 29) , were also available for immunohistochemical studies. AML cases (20 M0 , 21 M1, 28 M2, 15 M3, 28 M4, 18 M5, 15 M6 , and 10 M7) included bone marrow biopsies from 155 cases enrolled in the GIMEMA LAM99P trial and paraffin blocks from 5 cases of granulocytic sarcomas (bone 3 and skin 2). In all of the cases, histologic examination was done on 3 m-thick sections that were stained with H&E, Giemsa, and Gomori silver impregnation for reticulin fibers. All of the cases were classified according to the FAB/WHO criteria (30 -32) on the basis of the morphologic evaluation of tissue sections and May-Grunwald-Giemsa-stained marrow smears that were integrated by the results of standard cytochemical, immunohistochemical, and flow-cytometric studies.
Human Cell Lines. PAX5 expression was tested in two human myeloblastic cell lines: SKNO1 (kindly provided by Dr. Francesco Grignani, Institute of Internal Medicine, University of Perugia, Perugia, Italy), which bears the AML1-ETO gene rearrangement, and U937 (purchased from the American Type Culture Collection, Rockville, MD).
Cytogenetic and Molecular Studies. Cytogenetic and molecular studies were available in all of the 160 AML cases. Banded chromosomes were analyzed with standard methods and identified by GTC banding. At least 20 metaphases were examined for each case. Molecular studies for the major genetic alterations (PML-RAR␣, AML1/ETO, CBF␤/MYH11, rearrangement of MLL, DEK-CAN, and BCR-ABL) were done as described previously (33) (34) (35) .
Antibodies for Immunohistochemistry. PAX5 was detected with a specific IgG1 mAb directed against a fixative-resistant epitope located in the octamer/homeodomain regions of the PAX5 protein (Transduction Laboratories, San Diego, CA). Mouse mAbs directed against CD20, CD15, CD68(KP1), glycophorin A, CD34, and polyclonal antibodies against myeloperoxidase and CD3 were all purchased from DakoCytomation (Glostrup, Denmark). The anti-CD79a (clone JCB117) antibody was generously provided by Dr. David Y. Mason (Nuffield Department of Clinical Laboratory Services, John Radcliffe Hospital, Oxford, United Kingdom). The PG-M1 mAb directed against the macrophage-restricted form of the CD68 protein was generated in the laboratory of one of the authors (Brunangelo Falini; ref. 36) .
Tissue Processing. Bone marrow biopsies were fixed in B5 for 2 hours, decalcified in EDTA for 4 hours, and routinely processed for paraffin embedding (37) . Biopsies from extramedullary sites were fixed in formalin or B5 and embedded in paraffin. Paraffin sections (3-m thick) were dewaxed in three changes of xylene, attached on silane-coated slides, rehydrated, subjected to microwaving (750 W ϫ three cycles of 5 minutes each) with 1 mmol/L EDTA buffer (pH 8.0) as antigen retrieval solution (38) , and cooled.
Immunostaining Procedure. Immunostaining of antigen-retrieved tissue sections and cytological samples with mAbs was done with the alkaline phosphatase antialkaline phosphatase complex technique (39) . Endogenous tissue alkaline phosphatase was inhibited with levamisole (39) . Immunostaining with rabbit polyclonal antibodies was done with a four-step procedure (40) . Briefly, slides were sequentially incubated with the primary rabbit antibody, followed by a mouse monoclonal antirabbit antibody (Dako A/S, Glostrup, Denmark), a rabbit antimouse polyclonal antibody (Dako A/S, Glostrup, Denmark), and the alkaline phosphatase antialkaline phosphatase complexes. Slides were then counterstained in hematoxylin and mounted in Kayser's gelatin.
A case was considered positive by immunohistochemistry if 10% or more of the leukemic cells were stained by a given antibody. Positive controls were used for each reagent: they included reactive lymph nodes for PAX5, CD3, CD20, CD34, CD68, and CD79a and a spleen with myeloid metaplasia for CD15, myeloperoxidase, and glycophorin A. The same samples without the application of the primary antibody were run as negative controls. Double Immunoenzymatic Labeling. Antigen-retrieved paraffin sections from normal and leukemic bone marrows were double stained for PAX5 and either CD20, CD79a, or CD3. In the CD20/PAX5 and CD3/PAX5 double stainings, the CD20 and CD3 molecules were detected by a biotin-avidin peroxidase technique with diaminobenzidine/hydrogen peroxide (Sigma-Aldrich, Milan, Italy) as substrate, whereas the PAX5 protein was revealed by the alkaline phosphatase antialkaline phosphatase procedure (39) with naphtol AS-MX plus Fast Blue BB salt (both purchased from Sigma-Aldrich S.r.l.) as substrates (41) . In the CD79a/ PAX5 double stainings, the PAX5 molecule was detected by the immunoperoxidase technique with diaminobenzidine/hydrogen peroxide as substrate, whereas CD79a was revealed by the alkaline phosphatase antialkaline phosphatase complex procedure with naphtol AS-MX plus Fast Blue BB salt as substrates. Slides were mounted in Kayser's gelatin without counterstain.
Western Blotting Studies. AML cell lines and Ficoll-purified mononuclear cells from a t(8;21)-AML bone marrow sample with Ͼ85% blasts and Ͻ3% of residual CD20ϩ mature B cells were lysed with SDS loading buffer. An aliquot of each lysate was loaded onto a 12% SDS-acrylamide gel and electrotransferred to nitrocellulose sheets, following standard procedures. The membrane was subsequently incubated with nonfat dried milk (Bio-Rad, Hercules, CA) for 1 hour at room temperature followed by overnight incubation with the mAb against PAX5 horseradish peroxidase-conjugated antibody (Bio-Rad) was applied at 1:10,000 or 1:50,000, respectively, dilution in 0.05 mol/L TBS (pH 7.5) plus 0.1% Tween-20 at room temperature for 40 minutes. After washing in 0.05 mol/L TBS (pH 7.5) plus 0.1% Tween-20, results were visualized by enhanced chemiluminescence detection with ECL Plus reagents (Amersham Pharmacia Biotech, Little Chalfont, England). To check the amount of lysate loaded in each lane of the gel, nitrocellulose sheets were also probed for 2 hours with a goat antiactin polyclonal antibody (sc-1616, Santa Cruz Biotechnology, Santa Cruz, CA) diluted 1:200 in 0.05 mol/L TBS (pH 7.5) plus 0.1% Tween-20 followed by 40 minutes incubation with a secondary mouse antigoat-horseradish peroxidase-conjugated antibody (sc-2354, Santa Cruz Biotechnology) diluted 1:5,000 in 0.05 mol/L TBS (pH 7.5) plus 0.1% Tween-20.
Real-Time Reverse Transcription-PCR. In 16 AMLs cases [4 with normal karyotype, 4 with inv(16), and 8 with t(8;21)], total RNA was extracted following standard procedures from Ficoll-purified mononuclear cells deriving from bone marrow samples collected at disease onset and containing Ͼ80% blasts and Ͻ3% residual mature B-cells. First-strand cDNA synthesis was done with Superscript kit (Invitrogen-Life Technologies, Inc., Carlsbad, CA). In a 20-l reaction volume, 1 g RNA and 1 g of oligo(dT) [12] [13] [14] [15] [16] [17] [18] were mixed to a final volume of 11 L and incubated 10 minutes at 70°C. Then, 4 L of 5ϫ first-strand buffer, 2 L of DTT 0.1 mol/L, 1 L of 10 mmol/L deoxynucleoside triphosphate mix, and 2 L of Superscript reverse transcription were added. The sample was incubated 1 hour at 42°C and then diluted to 100 L in Tricine KOH 0.5 mol/L (pH 8.5). The subsequent real-time PCR was done in 25 L volume containing the following reagents: 0.5 mol/L of each primer, 12.5 L of 2ϫ SYBR Green PCR Master MIX, and 100 ng of template. The sequences of primer pairs were as follows: PAX5 forward primer, 5ЈCTGATCTCCCAGGCAAACAT3Ј; PAX5 reverse primer, 5ЈTTGCTCATCAAGGTGTCAGG3Ј; glyceraldehyde-3-phosphate dehydrogenase (GAPDH) forward primer, 5ЈATCAGCAATGCCTCCTGCAC3Ј; and GAPDH reverse primer, 5ЈTGGCATGGACTGTGGTCATG3Ј. Thermal cycling parameters were as follows: 2 minutes at 50°C, then 10 minutes at 95°C, followed by 40 cycles of 15 seconds at 95°C, and 1 minute at 60°C. Each sample was run in triplicate. The mean cycle-threshold (C T ) value for PAX5 and GAPDH across replicates of each sample was calculated (being C T the cycle number at which the PCR reaction reaches a predetermined fluorescence threshold and set within the linear range of all of the reactions). The amount of gene expression in a given sample was calculated as the difference (⌬C T ) between the mean C T value of the target mRNA (PAX5) and the mean C T value of the house-keeping mRNA GAPDH in that sample. Then, the difference (⌬⌬C T ) between the ⌬C T values of each t(8;21)-AML case and the mean ⌬C T value of the control cases was calculated. Finally, the relative expression value (i.e., the fold-change value) between each test sample and the control samples was calculated as 2 -⌬⌬CT .
RESULTS

PAX5 Expression in Normal and
Reactive Bone Marrow Samples. We first tested the ability of the anti-PAX5 mAb to detect the protein in B5-fixed/EDTA decalcified paraffin-embedded trephine biopsies from 35 normal and reactive bone marrows. In all of the samples, the antibody strongly labeled a small percentage (ranging from 1 to 5%) of lymphoid looking cells and occasional reactive lymphoid nodules (data not shown). As expected, expression of PAX5 was nuclear. Cells of the erythroid, myeloid, and megakaryocyte cell lineages were consistently PAX5-negative (data not shown) as well as bone marrow plasma cells, which in turn showed cytoplasmic CD79a staining (data not shown).
PAX5 Expression Correlates with That of CD79a in B-Cell ALLs. Blast cells from most B-cell ALL cases studied (142 of 150) coexpressed the CD79a and PAX5 molecules (Fig. 1) . PAX5 expression was invariably nuclear and highlighted the nuclear irregularities of leukemic cells, thus facilitating detection of minimal bone marrow infiltrates (especially in samples taken after chemotherapy; data not shown).
A few cases (8 of 150) not coexpressing PAX5 and CD79a were observed: 3 of them were PAX5 Ϫ /CD79a ϩ and the remaining 5 were Pax5 ϩ /CD79a Ϫ . This finding might be, at least in part, explained by denaturation of one or the other antigen related to fixation/embedding procedures. However, in 2 of 5 PAX5 ϩ /CD79a Ϫ cases, we were able to show that lack of CD79a expression in PAX5
ϩ leukemic cells was because of true absence of the protein (rather than to antigen denaturation); in fact, nonneoplastic mature B cells expressing CD79a were observed in close proximity to tumor cells and served as an internal positive control for CD79a staining (data not shown). These findings show that the PAX5 expression pattern closely parallels that of CD79a. Moreover, PAX5 can also correctly assign to B-lineage ALL cases unreactive to CD79a staining.
CD79a but not PAX5 Is Expressed in T-Cell ALLs. None of the 50 cases of T-cell ALL/lymphoblastic lymphoma expressed the PAX5 protein, whereas in 40% of cases (20 of 50), a variable percentage of leukemic cells (ranging from 30 to 100%) showed weak to moderate cytoplasmic positivity for the CD79a molecule (Fig. 2) .
These results clearly indicate that PAX5 is more specific than CD79a as immunophenotypic marker of B-cell ALLs, because it is not expressed in precursor T-cell malignancies.
Selective Expression of PAX5 in Myeloid Leukemias with t(8; 21). Bone marrow trephine biopsies from 160 AML patients, including 5 granulocytic sarcomas and fully characterized by cytogenetics and molecular studies (Table 1) , were analyzed for PAX5 expression. In 15 cases (including 2 granulocytic sarcomas), a percentage (ranging from 10 to 50%) of blast cells showed a weak to moderate nuclear labeling for PAX5. All cases expressed the CD68 and myeloperoxidase molecules (Fig. 3) and were classified as M2 according to the FAB/WHO classification (32) . Additional correlation with cytogenetic/molecular findings showed that all of the PAX5 ϩ cases displayed the t(8;21) translocation and were positive at reverse transcription-PCR analysis for the AML1/ ETO fusion transcript. However, PAX5 positivity was detectable by immunohistochemistry only in 15 of the 42 cases known to bear the t(8;21), among the 160 AML patients investigated, and only in a proportion of blast cells (but not in maturing leukemic cells). These results indicate that among AML, nuclear labeling for PAX5 is specific for the t(8;21) translocation, although only about one-third of cases (15 of 42) expressed the protein.
To provide additional evidence that the nuclear staining observed at immunohistochemistry with the anti-PAX5 mAb in t(8;21)-AML blasts is really due to the presence of the PAX5 protein (and not to a crossreacting unrelated nuclear protein), we performed Western blotting studies (with the same antibody) on lysates of primary blasts from a PAX5 ϩ t(8;21)-AML patient and of a myeloblastic cell line (SKNO1) bearing the t(8;21) translocation and expressing the AML1-ETO fusion protein: in both of them, we found a specific band of the expected molecular weight (M r 50,000) of PAX5 (Fig. 4) . To additionally study the expression of PAX5 in t(8;21)-AML, we next analyzed by quantitative reverse transcription-PCR the levels of PAX5 mRNA in 8 t(8;21)-AML patients (4 were PAX5-positive and 4 were PAX5-negative at immunohistochemistry) and compared them to 8 control patients devoid of this translocation ([4 of which had inv (16) and 4 had normal karyotype]. Notwithstanding their different PAX5 expression at the protein level, all of the 8 t(8;21)-AML samples showed a similar up-regulation of the PAX5 transcript: in fact, PAX5 mRNA was found to be increased over controls from 6-to 72-fold in the 4 cases that were PAX5-positive at immunohistochemistry and from 9-to 69-fold in the 4 cases that were PAX5-negative at immunohistochemistry (Fig. 5) . These findings confirm that PAX5 expression is specific for the t(8;21)-AML and indicate that within this subgroup of myeloid leukemias, the PAX5 gene is apparently expressed in more cases than it can be appreciated by immunohistochemistry alone.
PAX5 Expression in t(8;21)-AMLs Correlates with That of CD19 and CD79a.
Prompted by the fact that the transcription factor PAX5 exerts his master role in B-lymphopoiesis by trans-activating B-cell specific genes, we investigated whether the presence of PAX5 in t(8;21)-AML might result in the up-regulation of other B-cell molecules. To this end, we focused on CD79a and CD19 because: (a) these two immunologic markers, routinely used for B-cell ALL diagnosis, represent well-known transcriptional targets of PAX5 in B cells (4, 7, 8) ; (b) their expression pattern during B-cell development parallels that of PAX5, including down-regulation at the plasma cell stage; and (c) the expression of one of them (i.e., CD19) has been reportedly associated to t(8;21)-AML (42) . In 5 of 15 t(8;21)-AML cases displaying PAX5 expression at immunohistology, CD79a expression was detected in the same myeloid blast population expressing PAX5, as shown by double staining experiments (Fig. 3) . Flow cytometric data on CD19 expression (no anti-CD19 Ab being suitable for paraffin immunohistochemistry) were available for 3 of these 5 PAX5 ϩ /CD79a ϩ cases, and 2 of 3 cases were also found to be CD19 ϩ . As far as it concerns the remaining 10 cases that were PAX5 ϩ at immunohistology and the 4 cases that were PAX5 ϩ only at real-time reverse transcription-PCR, we were able to retrieve flow cytometric information for 4 of 10 and 3 of 4 of them, respectively, and found CD19 expression in 3 of 4 and 2 of 3, respectively. Taken together, these observations strongly suggest that PAX5 up-regulation in t(8;21)-AML is involved in the expression of CD79a and/or CD19 frequently observed in this subset of acute leukemias (10 of 12 evaluable cases in our study).
DISCUSSION
This article presents new data on PAX5 expression in acute leukemias that are both of biological and clinical value. In fact, we provide evidence that PAX5 expression in B-cell ALL closely parallels that of CD79a, the most useful marker currently available for B-cell ALL diagnosis in routine bone marrow biopsies (43) . There are several arguments for proposing that PAX5 should be added to CD79a (43, 44) as a new tool for the diagnosis of B-cell ALL. In particular, detection of PAX5 might be of particular aid in correctly diagnosing those B-cell ALL cases, which are unreactive to CD79a due either to denaturation or, more rarely (2 of 150 cases in our series), to true absence of the protein.
Moreover, the results of this study clearly indicate that PAX5 is a more specific marker than CD79a for lineage assignment in ALL. In fact, unlike CD79 that is known to be expressed in about 40% of T-lymphoblastic leukemias/lymphomas (28, 29) , the PAX5 protein was not detectable in any of the T-cell ALL cases investigated (including cases CD3 ϩ / CD79a ϩ ). These immunohistochemical findings are in keeping with the previous observation that among 17 cases of CD3 ϩ /CD79a ϩ T-cell ALL, none was found to be rearranged for IgH genes, 12 being only rearranged for TCR␥ genes, and 5 showing neither TCR␥ nor IgH genes rearrangements (29) . Taken together, DNA probe studies (29) and PAX5-immunostaining clearly show that CD3 ϩ /CD79a ϩ T-cell ALL represent cases of T-cell lineage leukemias (regardless of CD79a expression) rather than examples of biphenotypic leukemias.
Surprisingly, leukemic cells from a fraction of AML cases in this study were found to express PAX5 by immunohistochemistry. All cases turned out to bear the t(8;21) translocation that causes the AML1 gene to fuse with the ETO gene (45) . Moreover, by extending the analysis of PAX5 expression at the mRNA level, we were able to show a consistent up-regulation of this gene also in cases apparently negative at immunohistology. The reason why only one-third of t(8;21)-AMLs display PAX5 positivity at immunohistochemistry are presently not fully understood, but denaturation of the PAX5 protein (less abundantly expressed in t(8;21)-AML than in B-cell ALL) because of fixation/embedding procedures may, at least in part, explain this finding. It is not yet clear why only a proportion of blast cells (and not maturing leukemic cells) expresses PAX5. Although this might theoretically be due to technical reasons as well, it could also be that a selective expression of PAX5 indeed occurs in a specific subset of blasts possibly characterized by additional genetic evolution.
The observation that PAX5, the master regulator of B-lymphopoiesis, is expressed in t(8;21)-AMLs sheds new light on the previously reported association (42) between acute myeloid leukemias bearing the t(8;21) and expression of the CD19 gene, the transcription of which in B-cell is strictly dependent on PAX5 (4). Importantly, we showed for the first time that CD79a (another major PAX5 transcriptional target in B cells) can also be expressed in t(8;21)-AMLs. However, conversely to previous observations (46) reporting CD79a expression in 9 of 10 acute promyelocytic leukemias with t(15;17), CD79a positivity was never detected in any AML cases (including 17 acute promyelocytic leukemias) other than those with t(8;21). The differences between our results and the results of others (46) are likely due to the reagents used: in fact, we used the mAb JCB117 (43) , which is known to be more specific than the mAb HM57 used by other investigators (46) .
Based on the finding that the same myeloperoxidase-positive myeloid blast population coexpresses PAX5 and CD79a, we propose that the aberrant expression of B-cell molecules, such as CD19 and CD79a in t(8;21)-AMLs, is a PAX5-dependent phenomenon. Because AML1 binds in vitro to PAX5 through its Runt domain (which is retained in the AML1-ETO fusion protein) and cooperates with PAX5 in the activation of the B cell-specific blk gene promoter (47) , one could speculate that the interaction of PAX5 and AML1-ETO, which can theoretically occur in t(8;21)-AML blasts, might lead to a functional cooperation of these two proteins in the transcription of PAX5 target genes, such as CD79a and CD19. Additional studies are warranted to test this hypothesis as well as to clarify the mechanism leading to deregulated expression of PAX5 in t(8;21)-AML.
The finding that CD79a can be expressed both in PAX5-positive t(8;21)-AMLs and in PAX5-negative T-cell ALLs may be, at least in part, explained by the fact that the activity of the CD79a gene promoter is positively regulated not only by PAX5 but also by PU.1 (48) , an Ets-domain transcription factor involved both in myeloid and lymphoid development (49) . Intriguingly, PU.1 has been shown to be expressed in early precursor T cells (50 -52) as well as in a subset of T-lineage acute lymphoblastic leukemias (25) , and to be inactivated by the AML1-ETO fusion protein in t(8;21)-acute myeloid leukemias (53), thus potentially accounting for the CD79a up-regulation in T-cell ALL but not in t(8;21)-AML.
In addition to raising biological issues, these results are of practical value. Because there are no available mAbs recognizing fixative-resistant epitopes of the CD19 molecule on paraffin sections, labeling for PAX5 is a valuable tool for recognizing the t(8;21) translocation directly on routine bone marrow trephines. Immunostaining for PAX5 may be of particular value for the detection of AML cases with t(8;21) presenting as extramedullary masses (granulocytic sarcoma; refs. 54, 55) . In fact, under these circumstances, material for cytogenetic or molecular studies is frequently not available. Although, in the context of our large and representative panel of AMLs, nuclear expression of PAX5 appeared specific for t(8;21), it should be underlined that this finding is only observed in about one-third of cases and that we cannot formally rule out the possibility that PAX5 might be expressed in AML cases bearing rare chromosomal rearrangements that are not included in our series. Therefore, although representing an important clue in the immunohistochemical recognition of t(8;21), PAX5 nuclear labeling must be regarded, in the evaluation of AMLs, as an integration to cytogenetic and molecular studies that, when possible, should always be done.
In conclusion, the results presented in this paper provide the fol- lowing evidence: (a) PAX5 is a more specific marker than CD79a for immunophenotyping of ALL, and it can also be used to correctly assign to the B-lineage CD79a-negative cases; and (b) PAX5 expression in AML selectively associates with t(8;21) translocation, serving as a new tool for the recognition of this translocation in routine biopsies and likely accounting for the expression of other B-cell genes (CD19 and CD79a) in this myeloid neoplasm.
